Breaking Down BBVA’s Q3 2024 Earnings: A Comprehensive Analysis of Banco Bilbao Vizcaya Argentaria’s Financial Performance Description: Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) Q3 2024 Earnings Conference Call took place on October 31, 2024, at 4:30 AM ET. The key speakers included Patricia Bueno from Investor Relations, Onur Genc as the Chief Executive Officer, and…

Exelixis’s Cabometyx Driving Revenue Growth and Outlook for 2024 Expanding Oncology Portfolio and Shareholder-Friendly Initiatives Exelixis recently announced that their flagship drug, Cabometyx, continues to drive revenue growth, leading to a raised 2024 revenue forecast of $2.15–$2.2 billion. This positive news comes as the company plans to diversify its oncology portfolio by launching one new…

NewOrigin Gold Corp Finalizes Business Combination with Harfang Exploration Inc. NewOrigin Gold Corp, a leading mining company based in Toronto, Ontario, has recently announced an exciting development in its business operations. The company has received the final order from the Ontario Superior Court of Justice for its proposed business combination with Harfang Exploration Inc. This…

Invesco Closed-End Funds Pay Dividends: A Professional, Educated, and Profit-Focused Update for Blog Readers ATLANTA , Oct. 31, 2024 /PRNewswire/ The Board of Trustees (the “Board”) of each of Invesco High Income Trust II and Invesco Senior Income Trust (each, a “Fund” and collectively, the “Funds”) today announces the payment of the following dividends: EX-DATE…

Insmed Incorporated Reports Total Revenue of $93.4 Million for the Third Quarter of 2024 Business Update and Financial Results Insmed Incorporated, a global biopharmaceutical company, announced a total revenue of $93.4 million for the third quarter of 2024, which represents an 18% growth compared to the same period in 2023. The company also provided updates…

Revolutionizing Alzheimer’s Treatment: Anavex’s Blarcamesine Proves Effective in Phase IIb/III Trial – Presented at CTAD Conference 2024 Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer’s disease patients with good comparative…